sptl-3 Antibody

What is the SST3 antibody and what epitope does it recognize?

The non-phospho-SST3 receptor antibody is directed against the distal end of the carboxyl-terminal tail of human Somatostatin Receptor 3. Specifically, it recognizes a synthetic peptide with sequence QLLPQEASTGEKSSTMRISYL corresponding to amino acids 398-418 in human SST3. This antibody detects total SST3 receptors independent of their phosphorylation state, making it valuable for studies requiring comprehensive receptor visualization . The antibody is typically produced in rabbit hosts and is available as a polyclonal IgG that has undergone antigen affinity chromatography purification to ensure specificity . Understanding the precise epitope recognition is crucial when designing experiments requiring detection of specific protein domains or when working with mutated variants of the receptor.

What applications is the SST3 antibody validated for?

The SST3 antibody has been validated for multiple experimental applications including Western Blot (WB) at 1:1000 dilution, Immunocytochemistry (ICC) at 1:200 dilution, and Immunohistochemistry (IHC) at 1:100 dilution . Validation studies have confirmed its efficacy in transfected HEK293 cells where it successfully discriminates between native HEK293 cells (MOCK) and those stably expressing SST3 receptors. In immunocytochemical applications, this antibody can reveal the subcellular localization of SST3, demonstrating that receptors are confined to the plasma membrane in untreated cells but relocate to perinuclear clusters of vesicles after exposure to somatotropin release inhibiting factor (SRIF) . These validation parameters are essential for researchers to understand when designing experiments to ensure reliable and reproducible results.

How should SST3 antibodies be stored and handled to maintain efficacy?

Proper storage and handling of the SST3 antibody is critical to maintaining its functional integrity. The antibody is typically provided in liquid form in Dulbecco's PBS (pH 7.4) containing 150 mM NaCl and 0.02% sodium azide as a preservative . For short-term storage (up to several weeks), the antibody should be kept at 4°C. For long-term storage, -20°C is recommended to prevent degradation . It's important to avoid repeated freeze-thaw cycles as this can lead to denaturation and loss of binding capacity. When working with the antibody, aliquoting into single-use volumes is advisable to minimize freeze-thaw cycles. Additionally, researchers should be aware that sodium azide is a common preservative in antibody preparations but can inhibit horseradish peroxidase activity, so thorough washing steps are necessary when using detection systems based on this enzyme.

How can I distinguish between phosphorylated and non-phosphorylated forms of SST3 in experimental settings?

Distinguishing between phosphorylated and non-phosphorylated forms of SST3 requires careful antibody selection and experimental design. The non-phospho-SST3 antibody detects the receptor regardless of its phosphorylation state, making it suitable for studies of total receptor expression and trafficking . For phosphorylation-specific detection, researchers would need phospho-specific antibodies that recognize particular phosphorylated residues. When conducting comparative studies of receptor activation states, it's recommended to use both phospho-specific and non-phospho antibodies on parallel samples. Western blot analysis can reveal mobility shifts associated with phosphorylation, while immunoprecipitation with the non-phospho antibody followed by phospho-specific detection can quantify the proportion of receptors in each state. Importantly, when studying receptor internalization dynamics, the non-phospho antibody can track total receptor pools while phospho-specific antibodies may reveal activated receptor subpopulations, providing complementary data on receptor regulation mechanisms.

What are the critical considerations for antibody validation when studying SPTL tissues?

When studying Subcutaneous Panniculitis-like T-cell Lymphoma (SPTL) tissues, antibody validation becomes particularly crucial due to the complex immunological microenvironment. Researchers must establish specificity, selectivity, and reproducibility specifically in the context of SPTL samples . Key validation steps include:

• Positive and negative controls: Use known positive tissues (e.g., confirmed SPTL cases) and negative controls (non-malignant panniculitis) to confirm staining patterns .

• Epitope specificity verification: Ensure the antibody recognizes the intended target protein in SPTL tissue by comparing results with alternative detection methods or antibodies targeting different epitopes of the same protein .

• Cross-reactivity assessment: Test for potential cross-reactivity with similar proteins, particularly important in SPTL research given the inflammatory background rich in immunological markers .

• Performance in relevant assay conditions: Validate the antibody under the specific fixation and processing conditions used for SPTL tissues, as these can significantly affect epitope accessibility .

• Reproducibility testing: Confirm consistent staining patterns across multiple SPTL samples and between different lots of the same antibody .

In SPTL research, where distinguishing malignant T-cells from reactive inflammatory cells is critical, dual immunohistochemistry with lineage-specific markers (e.g., CD8 co-staining) may be necessary to precisely characterize the cellular source of immunological markers .

How can I optimize double immunostaining protocols for detecting SST3 in relation to immune checkpoint molecules?

Optimizing double immunostaining protocols for detecting SST3 in relation to immune checkpoint molecules requires careful consideration of antibody compatibility, detection systems, and sequential staining approaches. Based on research methodologies used in related fields, the following optimization strategies are recommended:

• Antibody selection: Choose primary antibodies from different host species (e.g., rabbit anti-SST3 and mouse anti-checkpoint molecule) to avoid cross-reactivity during secondary antibody application . If antibodies from the same species must be used, consider directly conjugated antibodies or sequential immunostaining with intermediate blocking steps.

• Detection system optimization: For fluorescent detection, select fluorophores with minimal spectral overlap. For chromogenic detection, use contrasting chromogens (e.g., DAB and Fast Red) and optimize development times to achieve clear visual distinction .

• Antigen retrieval compatibility: Determine a retrieval method that preserves epitopes for both targets. If different retrieval methods are required, sequential staining with separate retrieval steps may be necessary .

• Signal amplification balance: Adjust amplification methods (e.g., tyramide signal amplification) for each marker to achieve comparable signal intensities, particularly important when one target is expressed at significantly lower levels .

• Validation controls: Include single-stained controls alongside double-stained samples to verify that the presence of one detection system does not interfere with the other .

This approach has been successfully employed in studies examining CXCR3 and CD8 co-expression in SPTL samples, where researchers could distinguish malignant lymphocytes rimming adipocytes from non-malignant inflammatory cells .

What strategies can address non-specific binding when using SST3 antibodies in tissue samples?

Non-specific binding is a common challenge when using antibodies in tissue samples, especially in diagnostically complex contexts like SPTL. Several methodological approaches can minimize this issue:

• Blocking optimization: Extend blocking time (30-60 minutes) using a combination of serum (from the same species as the secondary antibody), BSA (1-3%), and non-ionic detergents like Triton X-100 (0.1-0.3%) to reduce hydrophobic interactions causing non-specific binding .

• Antibody titration: Perform systematic dilution series to identify the optimal concentration that maximizes specific signal while minimizing background. For SST3 antibody, starting with the recommended dilutions (1:100 for IHC) and testing a range above and below is advisable .

• Secondary antibody selection: Use highly cross-adsorbed secondary antibodies specifically tested against the tissue species being examined to reduce cross-reactivity with endogenous immunoglobulins .

• Endogenous enzyme inhibition: When using enzymatic detection systems, thoroughly block endogenous peroxidase (with 0.3-3% H₂O₂) or alkaline phosphatase (with levamisole) before antibody application .

• Autofluorescence reduction: For fluorescent detection, implement autofluorescence quenching steps such as treatment with Sudan Black B (0.1-0.3%) or photobleaching protocols particularly important in adipose-rich tissues common in SPTL samples .

• Validation controls: Include isotype controls matched to the primary antibody to distinguish between specific binding and Fc receptor interactions. Additionally, pre-absorption of the antibody with its immunizing peptide should eliminate specific staining while leaving non-specific background unaffected .

These approaches should be systematically tested and documented to establish optimal conditions for each specific tissue type and experimental question.

How does antibody affinity affect experimental outcomes in receptor internalization studies?

Antibody affinity significantly impacts experimental outcomes in receptor internalization studies, particularly when tracking dynamic processes like SST3 trafficking. Higher affinity antibodies (with lower dissociation constants) generally provide more sensitive detection but may also influence the biological processes being studied . Several considerations are important:

The SST3 antibody's ability to detect receptors in both membrane-localized and internalized vesicular states makes it valuable for trafficking studies, but these methodological considerations must be addressed for accurate interpretation .

What are the most effective protocols for quantifying SST3 expression across different experimental systems?

Quantifying SST3 expression across different experimental systems requires selecting appropriate methods based on research questions and available samples. Several validated approaches include:

• Western blot quantification: For cell lysates and tissue homogenates, Western blot using the non-phospho-SST3 antibody at 1:1000 dilution provides reliable protein quantification . Densitometric analysis of bands normalized to housekeeping proteins (e.g., GAPDH, β-actin) enables relative quantification. This method has been validated in HEK293 cell systems expressing SST3.

• Quantitative immunohistochemistry: For tissue sections, quantitative analysis of immunohistochemical staining using the antibody at 1:100 dilution can be performed through:

  • H-score methodology (combining staining intensity and percentage of positive cells)

  • Digital image analysis with color deconvolution algorithms

  • Automated counting of positively-stained cells in defined tissue compartments

• Flow cytometry: For cell suspensions, flow cytometric analysis provides single-cell resolution of receptor expression across populations. The antibody concentration requires optimization for this application, typically starting with 1-5 μg per 10⁶ cells.

• qRT-PCR complementation: While not directly measuring protein, quantitative RT-PCR provides complementary mRNA expression data that can validate antibody-based protein measurements. This approach has been successfully used in SPTL research, showing 10-350 fold expression differences when comparing target genes like CXCR3 and IDO-1 .

• Comparative analysis framework: When comparing across systems, implementing a standard reference sample analyzed in parallel with experimental samples enhances data normalization and comparability .

These approaches should be validated for each specific experimental system, with appropriate positive and negative controls included in every experiment.

How can I design experiments to investigate SST3 involvement in the immunosuppressive tumor microenvironment?

Designing experiments to investigate SST3 involvement in immunosuppressive tumor microenvironments requires multifaceted approaches drawing on methodologies demonstrated in related immunological research. Based on studies of immunosuppressive mechanisms in SPTL and immune checkpoint interactions, the following experimental design is recommended:

• Spatial protein expression mapping: Implement multiplex immunohistochemistry combining SST3 antibody with markers of:

  • Immunosuppressive mediators (e.g., IDO-1, which was highly expressed in SPTL samples)

  • Regulatory T cells (FoxP3+)

  • Cytokine signaling (IFNG, CXCR3, CXCL9)
    This approach can reveal spatial relationships between SST3-expressing cells and immunoregulatory components.

• Functional co-culture systems: Establish co-culture models with:

  • SST3-expressing cells (either natural or transfected)

  • Immune effector cells (T cells, NK cells)

  • Measure functional outcomes (proliferation, cytokine production, cytotoxicity)

  • Add somatostatin analogs to modulate SST3 signaling

• Receptor signaling analysis: Examine downstream effects of SST3 activation on immunomodulatory pathways through:

  • Phospho-flow cytometry for signaling intermediates

  • ELISA-based cytokine profiling

  • Gene expression analysis focused on immune tolerance mediators

• In vivo approaches: Design animal models with:

  • SST3-expressing tumors (transfected or naturally expressing)

  • Treatments with SST3 agonists/antagonists

  • Analysis of tumor infiltrating lymphocytes and immunosuppressive markers

• Correlation with clinical outcomes: For translational relevance, correlate SST3 expression patterns with:

  • Treatment responses

  • Immune infiltrate characteristics

  • Patient outcomes

This comprehensive approach integrates methodologies that have successfully revealed immunosuppressive mechanisms in lymphoma microenvironments, such as the upregulation of IDO-1 creating an immunotolerant environment favorable to malignant T cells .

What are the key differences between polyclonal and monoclonal antibodies in SST3 detection applications?

When selecting antibodies for SST3 detection, understanding the fundamental differences between polyclonal and monoclonal options is critical for experimental design and data interpretation:

The characterized non-phospho-SST3 antibody described in the search results is a polyclonal rabbit IgG that offers robust detection across multiple applications . For highly specialized applications like distinguishing between closely related receptor subtypes or precise epitope-specific studies, researchers might need to complement this with monoclonal alternatives after appropriate validation.

How does SST3 antibody performance compare to other receptor detection methods in lymphoma research?

When investigating receptor expression in lymphoma research, multiple detection methodologies exist beyond antibody-based approaches. Understanding their comparative advantages is essential for selecting optimal techniques:

• Antibody-based detection (e.g., SST3 antibody):

  • Advantages: Directly visualizes protein expression, enables subcellular localization, adaptable to multiple platforms (WB, IHC, flow cytometry)

  • Limitations: Dependent on antibody quality and validation, potential cross-reactivity, semi-quantitative unless carefully standardized

  • Performance metrics: The non-phospho-SST3 antibody demonstrates specificity in transfected cell systems and reveals receptor trafficking dynamics following ligand exposure

• mRNA quantification (qRT-PCR, RNA-Seq):

  • Advantages: Highly quantitative, high dynamic range, comprehensive when using genome-wide approaches

  • Limitations: Does not confirm protein expression or localization, post-transcriptional regulation not captured

  • Comparative performance: In SPTL research, qRT-PCR showed higher fold-change sensitivity (30-350 fold) than protein detection methods for certain markers, complementing protein-level findings

• Radioligand binding assays:

  • Advantages: Quantifies functional receptors with precise binding kinetics, high sensitivity

  • Limitations: Requires radioactive materials, limited spatial information, measures only ligand-accessible receptors

  • Applicability: Particularly valuable for pharmacological characterization of SST3 interactions

• Reporter systems (FRET-based, bioluminescence):

  • Advantages: Real-time monitoring, functional readouts, reduced background

  • Limitations: Requires genetic engineering, potential interference with native receptor function

  • Implementation considerations: Valuable for mechanistic studies but less applicable to primary clinical samples

• Mass spectrometry:

  • Advantages: Label-free detection, high specificity, potential for absolute quantification

  • Limitations: Lower sensitivity for membrane proteins, complex sample preparation, expensive

  • Emerging applications: Increasingly valuable for validation of antibody specificity

In SPTL research specifically, combined approaches have proven most informative, with gene expression microarrays identifying candidate markers (e.g., IDO-1, CXCR3), qRT-PCR providing quantitative validation, and immunohistochemistry confirming cellular sources within the complex tumor microenvironment .

What emerging technologies are enhancing antibody-based detection of receptors in complex tissue microenvironments?

The landscape of antibody-based detection is rapidly evolving, with several emerging technologies particularly relevant to studying receptors like SST3 in complex tissue microenvironments:

• Multiplexed immunofluorescence/immunohistochemistry:

  • Advanced multiplexing techniques now allow simultaneous detection of 30+ markers in a single tissue section through cyclic immunofluorescence, spectral unmixing, or metal-tagged antibodies

  • Applications: This approach would enable comprehensive mapping of SST3 expression in relation to multiple cell types and functional markers within the tumor microenvironment, similar to the dual staining approaches used for CXCR3/CD8 in SPTL research

  • Implementation considerations: Requires automated image acquisition and computational analysis pipelines

• Spatial transcriptomics integration:

  • Combining antibody detection with spatially-resolved transcriptomics provides correlative protein-mRNA data at near-single-cell resolution

  • Benefits: Would resolve questions about transcriptional regulation of SST3 and its relationship to protein expression in distinct microenvironment niches

  • Methodological approach: Antibody staining is performed on the same or serial sections used for spatial transcriptomics, with computational alignment of datasets

• Proximity ligation assays (PLA):

  • PLA technology detects protein-protein interactions with high specificity and sensitivity through antibody-conjugated oligonucleotides

  • Research applications: Could reveal SST3 interactions with signaling partners or other receptors at the molecular level, providing mechanistic insights beyond simple expression patterns

  • Technical advantages: Single-molecule sensitivity in intact tissue sections

• Intravital microscopy with fluorescent antibody fragments:

  • Minimally invasive visualization of receptor dynamics in living tissues using antibody-derived imaging agents

  • Potential insights: Could track SST3 trafficking and internalization in real-time in response to ligand binding or therapeutic interventions

  • Technical requirements: Development of fluorescent SST3 antibody fragments with appropriate pharmacokinetic properties

• Mass cytometry and imaging mass cytometry:

  • Metal-tagged antibodies enable highly multiplexed analysis of cell suspensions (CyTOF) or tissue sections (IMC)

  • Comparative advantages: No spectral overlap issues, facilitating comprehensive phenotyping of SST3-expressing cells within heterogeneous microenvironments

  • Implementation strategy: Would require metal conjugation and validation of the SST3 antibody

These technologies are transforming our ability to understand receptor biology in complex tissues, offering unprecedented resolution of spatial relationships and functional interactions. Their application to SST3 research would build upon existing methodologies that have successfully revealed the immunological complexity of lymphoma microenvironments .

How might understanding SST3 expression contribute to developing novel therapies for lymphomas?

Understanding SST3 expression patterns and functional roles could substantially impact lymphoma therapeutic development through several mechanistic pathways and clinical applications:

• Targeted drug delivery systems:

  • SST3-targeting antibodies could be utilized as delivery vehicles for cytotoxic payloads, similar to antibody-drug conjugates (ADCs) developed for other receptor targets

  • Specificity considerations: The validated SST3 antibody's specificity for human SST3 makes it potentially valuable for humanized preclinical models evaluating such approaches

  • Translational pathway: Clinical development would require further engineering to optimize tumor penetration and payload release

• Immunomodulatory approaches:

  • If SST3 signaling contributes to immunosuppressive microenvironments (as IDO-1 does in SPTL), receptor antagonism could enhance anti-tumor immunity

  • Experimental design: Studies combining SST3 modulation with immune checkpoint inhibitors like anti-LAG-3 (relatlimab) could reveal synergistic effects

  • Mechanistic rationale: Disrupting multiple immunosuppressive pathways simultaneously has shown enhanced efficacy in preclinical models

• Diagnostic and prognostic applications:

  • Validated antibody-based detection of SST3 could enable patient stratification based on receptor expression patterns

  • Implementation pathway: Development of standardized immunohistochemical protocols using the validated antibody, followed by correlation with treatment outcomes

  • Clinical utility: Could identify patients likely to benefit from SST3-targeted or combination therapies

• Receptor-mediated functional modulation:

  • SST3 agonists or antagonists could directly affect lymphoma cell growth, survival, and drug resistance mechanisms

  • Research approach: Functional studies in patient-derived xenografts using selective ligands and monitoring receptor internalization with the validated antibody

  • Therapeutic potential: Could provide alternative treatment options for refractory disease

• Combination therapy rational design:

  • Integrating SST3 expression data with other immunological markers (like IDO-1, CXCR3) could guide development of multi-targeted approaches

  • Preclinical evaluation: Testing combinations in humanized mouse models with appropriate receptor expression profiles

  • Translational perspective: Building upon successful dual-checkpoint blockade approaches like nivolumab+relatlimab

These approaches would build upon established methodologies in lymphoma research, where detailed molecular characterization has successfully identified therapeutic targets like IDO-1 in SPTL, creating an immunosuppressive microenvironment favorable to malignant cells .